Published 2026-09-15 · Theo Ledger
A fund built to own the companies disrupting incumbents has spent six months buying a 150-year-old pharmaceutical giant. It is either a contradiction or the most interesting thing in ARKG.
Eli Lilly (LLY) first appeared in ARK's daily files on 4 March 2026 . At the time it was a token holding worth about $12.9 million. It is now $111.9 million across 95,104 shares — a position roughly nine times larger than where it started.
The weighting is the interesting detail. This is overwhelmingly an ARKG position — a top-ten holding in the genomics fund — with only a token presence in the flagship.
ARK's stated purpose is owning companies that displace incumbents. Eli Lilly is the incumbent: founded in 1876, one of the largest pharmaceutical companies on earth, with the distribution muscle and regulatory apparatus that ARK's usual holdings are supposed to be routing around.
In this post
- The position
- Why this looks off-thesis
- The case that it is not off-thesis at all
- What it tells you about ARKG
- What to watch